PRMT5 and cancer: We hypothesized that the targeted inhibition of PRMT5 in NDRG2low ATL and solid cancer cells would specifically induce anti-cancer effects as synthetic lethality through the inhibition of cytoplasmic PRMT5/HSP90 activity.